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ABSTRACT 
Aim. The aim of our study was to evaluate the results of CEA and CAS in patients with carotid artery stenosis, and their effect on 
long-term mortality and morbidity, as well as to identify predictors of long-term mortality in a single-centre observational study.
Clinical rationale. While data on short-term morbidity and mortality after carotid endarterectomy (CEA) and carotid stenting 
(CAS) is robust, there is only a limited amount of literature on long-term mortality and its predictors five years-plus post these 
procedures.
Material and methods. Consecutive patients with symptomatic and asymptomatic internal carotid artery stenosis treated with 
CEA or CAS in a single centre in eastern Slovakia between 2012 and 2014 were included. We recorded basic sociodemographic 
data, the presence of co-morbidities and periprocedural complications. Clinical and sonographic follow-up was performed three 
and 12 months after the procedures. Patient survival data and any stroke data was obtained at the end of a six-year follow-up.
Results. We included 259 patients after CEA (mean age 67.4 ± 8.5, 64.5% men) and 321 after CAS (mean age 66.9 ± 8.4, 73.5% 
men). We did not identify a statistically significant difference in short-term or long-term mortality, survival times, or the presence 
of short-term or long-term complications between the CEA and CAS groups. Predictors of long-term mortality included age and 
diabetes mellitus in both cohorts. Repeated interventions were related to increased mortality only in the CAS cohort.
Conclusions. The results of our study show that long-term mortality does not differ between CEA and CAS. 
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Introduction
Stroke is the second most common cause of death and 
a leading cause of disability worldwide. Carotid stenosis is 
responsible for approximately 20% of all ischaemic strokes [1]. 
There is an accepted consensus on indications for the treatment 
of symptomatic carotid stenosis in secondary stroke prevention 
[2], but agreement on the treatment of asymptomatic stenosis 
is less consistent. Historically, there have been discussions 
about which revascularisation method should be the first 
choice, and how this choice affects long-term outcomes in pa-
tients after stroke. In this regard, data on long-term mortality 
and its predictors is somewhat limited. 
Therefore, the aim of our study was to evaluate the results 
of carotid endarterectomy (CEA) and carotid stenting (CAS) 
and their effect on long-term mortality, and to identify pre-
dictors of long-term mortality in the revascularisation centre 
for our referral area.
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This was a single-centre observational longitudinal fol-
low-up study.
Patients
All patients with symptomatic and asymptomatic stenosis 
of the carotid artery from eastern Slovakia who underwent 
extracranial carotid revascularisation (carotid endarterecto-
my at the Dept. of Vascular Surgery and carotid angioplasty 
stenting at the Dept. of Angiology, VUSCH Košice, Slovakia) 
between 2012 and 2014 were included in the study. A total of 
580 patients, 259 after carotid endarterectomy and 321 after 
carotid stenting, were included. No patient was excluded from 
the study by investigators. The choice of revascularisation 
treatment (CEA or CAS) was agreed by the treating vascular 
surgeon and the angiologist according to current guidelines 
and periprocedural risk evaluation, although the patient’s pref-
erence was also taken into account. Our study was performed 
according to the Declaration of Helsinki 1975; it was approved 
by the local ethics committee and all patients signed written 
informed consent prior to enrollment.
Data collection and procedures
Carotid stenosis was evaluated as symptomatic if patients 
had experienced ischaemic stroke or transient ischaemic attack 
(TIA) within the last six months. 
Carotid endarterectomy (CEA) was performed under 
general anaesthesia. A shunt was used selectively when brain 
oxygen saturation measured by perioperative transcranial 
monitoring was decreased by 20% of its normal value. Ever-
sion or the classical method was used. Patients scheduled for 
CEA received a single antiplatelet medication which was not 
discontinued for the surgery. 
Carotid stenting (CAS) was carried out following a stand-
ardised protocol; the percutaneous transfemoral approach 
under local anaesthesia was used. The most commonly used 
devices were XACT (Abbott), Protege (Medtronic), Cristallo 
Ideale (Invatec) and Sinus-Carotid (Optimed). All procedures 
were performed with cerebral protection devices, distal protec-
tion (filters), or a proximal protection device (Mo.Ma). Patients 
scheduled for CAS received antiplatelet therapy consisting of 
acetylsalicylic acid (mean dosage 100 mg/day) and clopidogrel 
(75 mg/day) for at least three days before and three months 
after CAS. Low-Molecular-Weight Heparin (LMWH) 3000- 
-5000 IU i.a. was given routinely after femoral artery puncture 
at the beginning of the procedure, and intravenous Atropin 
0.5–1.5 mg was used to prevent bradycardia.
Patients underwent a standard neurological examination 
after the revascularisation procedure, as well as three and 
12 months after the procedure. When a worsening of neuro-
logical findings was determined, a neuroimaging procedure 
(brain CT/MRI) was performed without delay. 
Duplex ultrasound examination of extracranial carotid ar-
teries was carried out three and 12 months after the procedure 
(Philips HD11XE, Philips Ultrasound, Bothell, WA, USA with 
linear 3–12MHz probe).  
Outcome measures
Stroke was defined as any new episode of neurological dys-
function caused by focal cerebral, spinal, or retinal infarction 
and classified as fatal, disabling (modified Rankin Score ≥ 3), 
or nondisabling (modified Rankin Score < 3). In addition, the 
presence of transient ischaemic attack defined as a new brief 
episode of neurological dysfunction caused by focal brain or 
retinal ischaemia, with clinical symptoms typically lasting 
less than one hour, and without evidence of acute infarction, 
were recorded.
The primary outcome was the combined risk of any stroke, 
or death within 30 days. Secondary outcomes were any stroke, 
disabling stroke, TIA, myocardial infarction, severe local com-
plications (after CAS) and non-severe complications (nerve 
palsy after CEA, hypotension and bradycardia after CAS). Late 
outcomes included the combined endpoint of ipsilateral stroke, 
restenosis (evaluated by ultrasound examination) after three 
and 12 months, 6-year mortality rate, and the occurrence of 
any stroke during those six years. Patient survival data at the 
end of the 6-year follow-up was obtained from the National 
Health Care Surveillance Authority for all included subjects. 
Data on the presence of any stroke during the follow up period 
was obtained from the National Centre of Health Information 
also for all included subjects, including date and type of event.
Statistical analyses
Statistical analyses were performed using statistical soft-
ware SPSS version 25.0 for Windows (SPSS Inc., Chicago, IL, 
USA). Firstly, we described the basic characteristics of subjects 
after CEA and CAS; differences between the groups were 
evaluated using the Chi-squared test and two-tailed t-test. 
Subsequently, characteristics of subjects who were alive or 
deceased by the end of follow-up for both groups after CEA 
or CAS were described, and differences were evaluated using 
the Chi-squared test and two-tailed t-test. Consequentially, 
variables that were significantly different between the alive 
or deceased groups were entered into a multinomial logistic 
regression separately for patients after CEA and CAS. Finally, 
Kaplan-Meier analyses, including Mantel-Cox log-rank test, 
were used to estimate the long-term survival for both groups 
and intervals free of stroke after the procedure in both groups. 
Results
Our sample consisted of 259 patients after CEA, with a mean 
age of 67.4±8.5 (64.5% men), and 321 patients after CAS, with 
a mean age of 66.9 ± 8.4 (73.5% men). Male gender was more 
common in the CAS group; however, this was only in the group 
of asymptomatic patients. Patients after CAS had more frequent 
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Table 1. Characteristics of study population based on type of intervention
CEA CAS Statistical significance
No. of patients 259 321 p = ns
Age 67.4±8.5 66.9 ± 8.4 p = ns
Sex (M/F) 167/92 236/92 p = 0.023
Past smoking 128 (49.4%) 180 (56.1%) p = ns
Current smoking 48 (18.5%) 71 (22.1%) p = ns
Atrial fibrillation 36 (13.9%) 37 (11.5%) p = ns
Diabetes mellitus 105 (40.5%) 125 (38.9%) p = ns
Arterial hypertension 243 (93.8%) 294 (91.8%) p = ns
Hyperlipidaemia 153 (59.1%) 168 (61.7%) p = ns
Hypercoagulation state 8 (3.1%) 23 (7.2%) p = 0.04
CHD or MI 164 (63.3%) 205 (63.9%) p = ns
PAD 54 (20.8%) 82 (25.5%) p = ns
Past stroke or TIA 166 (64.1%) 211 (65.7%) p = ns
Symptomatic stenosis 102 (39.4%) 112 (34.9%) p = ns
Stenosis > 70% 233 (90.0%) 304 (94.7%) p = 0.038
left/right 129 (50%) 164 (51.4%) p = ns
Severe complications within 30 days 15 (5.8%) 13 (4.0%) p = ns
Non-severe complications within 30 days 92 (35.5%) 59 (18.4%) p < 0.001
Severe complications after 3 months* 4/138 (2.9%) 10/181 (5.5%) p = ns
Non-severe complications after 3 months* 16/138 (11.6%) 4/181 (2.2%) p = 0.002
Severe complications within 12 months* 4/74 (5.4%) 6/53 (11.3%) p = 0.001
Verified restenosis – within 12 months* 6/120 (5.0%) 11/160 (6.9%) p = ns
Contralateral > 70% stenosis or occlusion 50 (19.3%) 89 (27.7%) p = 0.02
No complication within 30 days   
Type of severe complication within 30 days   
     Mild stroke or TIA
     Severe stroke
     Haemorrhagic stroke
     Any stroke 
     MI
Severe local complications at site of CAS


















Death by the end of follow-up 83 (32.0%) 93 (29.0%) p = ns
Repeated intervention 21 (8.1%) 37 (11.5%) p = ns
Presence of any stroke during 7-year follow up
     Ischaemic stroke
     Subarachnoid haemorrhage








CEA — carotid endarterectomy; CAS — carotid stenting; CHD — coronary heart disease; MI — myocardial infarction; PAD — peripheral artery disease; TIA — transient ischaemic attack; *patients who were 
re-examined including ultrasound after three and 12 months of follow-up  
hypercoagulation states, > 70% stenosis of the internal carotid 
artery (ICA), contralateral >70% stenosis or occlusion of ICA, 
and severe complications after 12 months. Patients after CEA 
had more frequent non-severe complications immediately af-
terwards as well as three months after the procedure.
No differences regarding time period between qualifying 
event (stroke/TIA) and procedure (CEA vs. CAS) were ob-
served (17.6 ± 25.6 vs. 19.5 ± 31.4 days; p = 0.62) in the group 
of symptomatic patients.
Detailed characteristics of the sample are set out in Table 1. 
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Table 2. Clinical characteristics of patients surviving and deceased after CEA and CAS
CEA CAS
Died Survived Statistical 
significance
Died Survived Statistical  
significance
No. of patients 83 176 93 223
Age 69.7 ± 7.8 66.1±8.6 p = 0.002 71.4 ± 8.8 65.5 ± 7.8 p < 0.001
Sex (M/F) 60/23 107/69 p = ns 72/21 164/64 p = ns
Past smoking 41 (50%) 87 (49%) p = ns 47 (50%) 133 (58%) p = ns
Current smoking 16 (19%) 32 (18%) p = ns 9 (10%) 62 (27%) p = 0.001
Atrial fibrillation 12 (14%) 24 (14%) p = ns 21 (23%) 16 (7%) p < 0.001
Diabetes mellitus 43 (58%) 57 (32%) p < 0.001 48 (52%) 77 (34%) p = 0.004
Arterial hypertension 78 (94%) 165 (94%) p = ns 86 (92%) 208 (91%) p = ns
Hyperlipidaemia 48 (58%) 105 (60%) p = ns 53 (57%) 145 (64%) p = ns
Hypercoagulation state 0 8 (5%) p = ns 6 (6%) 17 (7%) p = ns
CHD or MI 63 (76%) 101 (57%) p = 0.004 75 (81%) 130 (57%) p < 0.001
PAD 23 (28%) 31 (17%) p = ns 29 (31%) 53 (23%) p = ns
Past stroke or TIA 55 (66%) 111 (63%) p = ns 67 (72%) 144 (63%) p = ns
Symptomatic stenosis 38 (46%) 64 (36%) p = ns 39 (42%) 73 (32%) p = ns
Stenosis > 70% 71 (86%) 162 (92%) p = ns 87 (94%) 217 (95%) p = ns
Severe complications within 30 days 9 (11%) 6 (3%) p = 0.023 7 (8%) 6 (3%) p = 0.044
Non-severe complications within 30 days 27 (33%) 65 (37%) p = ns 16 (17%) 43 (19%) p = ns
Severe complications after 3 months 0 4 (4%) p = 0.003 5/50 (10%) 5/131 (4%) p = ns
Non-severe complications after 3 months 0 16 (16%) p = 0.001 2/50 (4%) 2/131 (2%) p = ns
Severe complications within 12 months 1/12 (8%) 3/61 (5%) p = 0.006 5/10 (50%) 1/43 (2%) p < 0.001
Verified restenosis within 12 months 1/26 (4%) 5/93 (5%) p = 0.009 6/43 (14%) 5/112 (5%) p = ns
Contralateral > 70% stenosis or occlusion 21 (25%) 29 (16%) p = ns 31 (33%) 58 (25%) p = ns
No complication within 30 days
Type of severe complication within 30 day  
     Mild stroke or TIA
     Severe stroke
     Intracerebral haemorrhage
     MI
Severe local insertion complications (CAS)






























Repeated intervention 8 (10%) 13 (7%) p = ns 17 (18%) 20 (9%) p = 0.016
Patients after CEA surviving at the end of follow-up had 
significantly younger age, less frequent diabetes mellitus (DM) 
coronary heart disease (CHD) or myocardial infarction (MI), 
less frequent severe complications immediately after the proce-
dure, and more frequent severe and non-severe complications 
three months after the procedure. 
Patients after CAS surviving at the end of follow-up had 
significantly younger age, less atrial fibrillation (AF), DM, 
CHD or MI, less frequent severe complications immediately 
after the procedure and repeated interventions. They were 
more commonly current smokers, and there was a significant 
difference among the types of complications within 30 days 
after the intervention. Detailed clinical characteristics of 
patients surviving and deceased after CEA and CAS are set 
out in Table 2.
In a multinomial logistic regression model controlled 
for all variables identified as statistically significant in Table 
2, 6-year mortality in the group after CEA was significantly 
related to DM (OR=2.28, 95% CI 1.27-4.08), older age (OR 
= 1.05, 95% CI 1.01-1.09) and severe complications within 
12 months (OR = 2.76, 95% CI 1.06-7.25). In the group 
of subjects after CAS, 6-year mortality was related to DM 
(OR = 1.96, 95% CI 1.12-3.42), older age (OR = 1.08, 95% CI 1.04- 
-1.12), severe complications within 12 months (OR = 3.40, 
95% CI 1.22-9.52), and repeated interventions (OR = 3.22, 
95% CI 1.34-7.69) (Tab. 3). 
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Table 3. Multinomial logistic regression — predictors of 6-year mortality in patients after CEA/CAS
CEA CAS
OR 95% CI 95 Significance OR 95% CI 95 Significance
Diabetes mellitus 2.28 1.27–4.081 p = 0.006 Diabetes mellitus 1.96 1.12–3.42 p = 0.018
Age 1.05 1.01–1.09 p = 0.018 Age 1.08 1.04–1.12 p < 0.001
Severe complications within 
12 months
2.76 1.06–7.25 p = 0.038 Severe complications 
within 12 months
3.40 1.22–9.52 p = 0.019
Repeated intervention 3.22 1.34–7.69 p = 0.009
In Kaplan-Meier analysis, the mean survival time in the 
CEA group during our follow up was 73.0 ± 2.0 months (95% 
CI 69.1-76.8). For the CAS group, it was 79.5 ± 1.8 months 
(95% CI 76.0-83.0). The Mantel-Cox log-rank test did not 
identify a statistically significant difference between survival of 
the CEA and CAS patient groups (Fig. 1A). The mean survival 
time free of stroke in the CEA group during our follow up was 
78.3 ± 1.6 months (95% CI 75.2-81.4). For the CAS group, it 
was 79.4 ± 1.7 months (95% CI 76.1-82.7). While the long-term 
prevalence of stroke was more common in the CAS group, 
the Mantel-Cox log-rank test did not identify a statistically 
significant difference between intervals free of stroke in the 
CEA and CAS patient groups (Fig. 1B).  
Discussion
Our results show that long-term mortality, as well as the 
long-term prevalence of stroke, does not differ between pa-
tients undergoing CEA and those undergoing CAS. 
Several previous studies and meta-analyses have reported 
increased short-term recurrence of any stroke or death within 
30 days or three months after CAS compared to CEA [3–6]. 
This was, however, not replicated in our study. We found 
no significant differences between CAS and CEA in any type 
of stroke (13 and 12, respectively, p = ns) or death (0 in both 
groups) after 30 days, or the prevalence of any severe com-
plications after three months. Similar findings were reported 
from the SPACE study, which did not show higher rates of 
ipsilateral stroke or death within 30 days after CAS or CEA 
(6.92% and 6.45%, respectively, RR 1.07 ITT) [7]. 
On the other hand, our finding that long-term mortality 
does not significantly differ after CEA or CAS is in line with 
most previous studies. After three years of follow-up, the CA-
VATAS study reported no difference in mortality or disabling 
stroke between CAS and CEA (14.3% vs. 14.2% HR 1.03) [8], 
and the SAPPHIRE study [9] verified no significant difference 
in the rate of death (18.6% vs. 21.0%, p = 0.68) or major and 
minor stroke (9.0% vs. 9.0%, p = 0.99) between CAS and CEA. 
Similar findings were shown in the CREST study [10], where 
the 4-year rate of stroke or death among symptomatic patients 
(CAS vs. CEA; 8.0% vs. 6.4%; HR 1.37, p = 0.14) did not statis-
tically differ. In the EVA-3S study [3] the 4-year risks of stroke 
or death or non-procedural stroke were higher in CAS-treated 
patients (11.1% vs. 6.2%, HR 1.97, p = 0.03); however, this was 
mostly attributed to the higher periprocedural risk of CAS, 
as the risk of ipsilateral stroke beyond 30 days was low and 
similar in both groups. 
The only study thus far conducted reporting a follow-up 
beyond 6 years is the extended CREST study, which did not 
report significant differences between any stroke or death 
after 10 years; however, the authors did not provide a value 
for 10-year mortality alone [11]. 
While the results of long-term mortality are fairly consist-
ent across studies, predictors of mortality are less homogene-
ous. In contrast to our study, where higher age was a predictor 
of mortality in both CEA- and CAS-treated patients, Brott 
et al. [11] found no correlations between risk factors (age, 
sex, stenosis type and status) and the rate of death or stroke. 
Similarly, Brott et al. [12] did not find any modifying effect of 
DM, hypertension, hyperlipidemia or cardiovascular diseases 
on long-term prevalence of stroke or death. These results are 
again in contrast to ours, as diabetes mellitus was a predictor 
of 6-year mortality in both CEA- and CAS-treated patients. 
Nevertheless, it is important to note that Brott et al. [2019] [12] 
did not differentiate between stroke and death in their analy-
ses, and thus the effect of these predictors on mortality alone 
cannot be compared directly. Also, in another study, Parlani 
et al. [13] found no relationship between stroke or death and 
the presence of DM; however, their findings in a CEA-treated 
group show a significantly increased risk of stroke or death 
when using insulin (6.5% vs. 1.7%; OR 3.93; p = 0.017).
We did not observe any significant differences in the rate 
of severe re-stenosis or occlusions between CEA and CAS 
after 12 months. However, patients after CAS needed more 
repeated interventions, which at the end were an independent 
predictor of long-term mortality in the CAS cohort. In contrast 
to our results, several other studies [7, 14] have linked CAS to 
a higher rate of moderate as well as severe stenosis (13% vs. 5%, 
p = 0.02; 10.7% vs. 4.6%, p = 0.009; respectively). 
Our study included all consecutive patients, respecting the 
standard inclusion criteria for both symptomatic and asymp-
tomatic stenosis [15], and all procedures were performed 
by the same team of surgeons and angiologists meeting the 
SAPPHIRE and CREST trial proficiency requirements, thereby 
reducing the heterogeneity of procedural outcomes. Never-
theless, some limitations need to be considered. In particular, 
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more detailed patient history regarding recurrent stroke and 
other comorbidities beyond 12 months follow-up, as well as 
cause of death, were not available. Also, patients were not 
assigned to the treatment groups randomly, and thus some se-
lection bias may have been implicated in treatment assignment.
Our results show that long-term mortality, as well as 
the long-term prevalence of stroke, does not differ between 
patients undergoing CEA and CAS. Further research is nec-
essary to better define predictors of mortality, which would 
be helpful in selecting the most appropriate procedure for 
our patients.
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Figure 1. Results of Kaplan-Meier analysis in 259 patients after CEA and 321 patients after CAS in terms of A. Long-term survival of sub-
jects after CEA and CAS, log-rank (Mantel-Cox) test chi-square 0.595, p = 0.441; B. Survival free of stroke after initial intervention, log-rank 
(Mantel-Cox) test chi square 1.457, p = 0.227
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